Pancreatic cancer is the fourth most common cause of cancer-related mortality in Europe.1 Despite increased awareness, most patients continue to present with advanced disease. There has been minimal improvement in survival rates over the past 30 years, with overall 5-year survival remaining less than 8%.2 While these disappointing results are due to a multitude of host and treatment variables, it is apparent that, for a significant number of patients, poor nutritional and performance status are limiting factors to treatment choice, delivery, and tolerance.